Genmab (GMAB): Projected Future Earnings

Genmab A/S (GMAB) generates revenue through payments and royalties from industry behemoths that implement the antibodies developed by the company. This chart illustrating the price evolution of the quotes shows profit at the level of 1.01. This result is supported by the intensive development of next-generation bispecific compounds and a streamlined biomaterial transportation system, ensuring high profitability and the stability of innovative drug supplies.

GMAB - genmab.com Expected Net Profit over the range 07/04/2022 - 11/12/2026

Financial and market metric breakdowns for Genmab AS (GMAB)

- price and consensus price forecast:

Price Chart Genmab A/S|GMAB - Average Forecast Price

- stock exchange capitalization data:

Market Capitalization Genmab|GMAB - Full Takeover Company Value

- book capitalization indicators:

Accounting Value per Share Genmab|GMAB - Total Stockholders' Equity|Market Cap to Net Assets Ratio genmab.com|GMAB - Aggregate Asset Value

- debt level and financial liquidity data:

- earnings and market ratios statistics:

GMAB - Company Net Income|Future Profit Genmab A/S|GMAB - Market Price to Net Income Ratio|Forward P/E Multiple Genmab|GMAB - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Genmab|GMAB - Operating profit before amortization|Net earnings per share for the last 12 months Genmab|GMAB - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months genmab.com|GMAB - Net earnings per one share growth for the current year|Earnings growth forecast for next year Genmab A/S

Basic company analysis:GMAB, Genmab A/S

This indicator assesses expected net profit adjusted for debt obligations and market conditions, allowing for a real-time comparison of the stock's potential against alternative assets. For Genmab A/S (GMAB), changes in projected earnings directly reflect the probability of clinical trial success and regulatory drug approvals, which determines the inflow of institutional capital or the risk of funds shifting into defensive assets.

Competitor analysis for Genmab A/S